Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | TYK2 | P29597 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25825682 | 0.92 | TAAR1 (0.85) | TAAR1MDM2SMN1; SMN2TP53EPHX1 | |
| SCHEMBL23069097 | 0.92 | TAAR1 (0.85) | TAAR1MDM2SMN1; SMN2TP53EPHX1 | |
| SCHEMBL10020286 | 0.91 | MDM2 (1.00) | TAAR1MDM2SMN1; SMN2EPHX1LMNA | |
| SCHEMBL31668740 | 0.89 | MDM2 (0.95) | TAAR1MDM2SMN1; SMN2EPHX1LMNA | |
| Diphenylurea SCHEMBL133103 | 0.86 | SMN1; SMN2 (1.00) | TAAR1SMN1; SMN2TP53EPHX1TSHR | |
| Diphenylurea SCHEMBL28431956 | 0.84 | SMN1; SMN2 (0.94) | TAAR1SMN1; SMN2TP53EPHX1TSHR | |
| Diphenylurea SCHEMBL29392345 | 0.84 | SMN1; SMN2 (0.94) | TAAR1SMN1; SMN2TP53EPHX1TSHR | |
| Diphenylurea SCHEMBL30786615 | 0.84 | SMN1; SMN2 (0.94) | TAAR1SMN1; SMN2TP53EPHX1TSHR | |
| Diphenylurea SCHEMBL3037927 | 0.84 | SMN1; SMN2 (0.94) | TAAR1SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL11059378 | 0.84 | SMN1; SMN2 (0.94) | TAAR1SMN1; SMN2TP53EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115530076-B | Winter jujube tissue culture method | 山东滨州国家农业科技园区管理服务中心(滨州黄河三角洲高效生态产业现代技术研究院) | 2023-05-26 | — | — | CN | claimed |
| CN-115530076-A | Winter jujube tissue culture method | 山东滨州国家农业科技园区管理服务中心(滨州黄河三角洲高效生态产业现代技术研究院) | 2022-12-30 | — | — | CN | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| CN-101723886-A | Method for synthesizing 1-(4-pyridyl)-3-phenylurea | UNIV NORTHWEST A&F | 2010-06-09 | — | — | CN | claimed |
| US-20080196121-A1 | Commercially viable process for in vitro mass culture of jatropha curcas | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-08-14 | — | — | US | claimed |
| US-20080194026-A1 | COMMERCIALLY VIABLE PROCESS FOR IN VITRO MASS CULTURE OF JATROPHA CURCAS | RELIANCE LIFE SCIENCES PVT, LTD. (IN) | 2008-08-14 | — | — | US | claimed |
| EP-1817956-A2 | Commercially viable process for in-vitro mass culture of jatropha curcas | Reliance Life Sciences Pvt., Ltd. (IN) | 2007-08-15 | — | — | EP | claimed |
| EP-0519758-A1 | Hyperproduction of shoots during in vitro regeneration of plant | UNIVERSITY OF GUELPH (CA) | 1992-12-23 | — | — | EP | claimed |
| JP-62106003-A | — | — | None | — | — | JP | disclosed |
| JP-62108802-A | — | — | None | — | — | JP | disclosed |
| JP-11332575-A | — | — | None | — | — | JP | disclosed |
| US-20260109845-A1 | SHAPE MEMORY POLYMER AND RESIN COMPOSITION THEREOF | NANO & ADVANCED MATERIALS INST LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| US-4308054-A | PLANT GROWTH REGULATORS | SATO, SUSUMU (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4242347-A | Hypotensive indolylalkylpiperidyl guanidines and isoureas | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4193788-A | N-(2-Chloro-4-pyridyl)ureas | ISOGAI YO (JP) | 1980-03-18 | — | — | US | disclosed |
| US-4147786-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4073911-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | TAAR1 4675/4885MDM2 1248/4885SMN1; SMN2 3999/4885 |
| US-20260109845-A1 | SHAPE MEMORY POLYMER AND RESIN COMPOSITION THEREOF | CD69, VSIG8, PUF60 | TAAR1 2674/4885MDM2 3478/4885SMN1; SMN2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.